The family of GATA-binding proteins (GATA factors) are transcriptional activators that interact specifically with a consensus WGATAR sequence or a related DNA sequence (see references 42 and 43 for reviews). Each vertebrate family member contains a highly conserved DNA-binding domain consisting of two similar repeats of a novel zinc finger. To date, cDNA clones encoding six distinct vertebrate family members (GATA-1 through GATA-6) have been characterized (2, 10, 23, 27, 58, 60, 65, 69, 71) . Each GATA factor gene is transcribed in a unique tissue-restricted pattern, and the different proteins are thought to function in the regulation of cell-specific gene expression. Related proteins, sometimes containing only the C-terminal finger, have also been isolated from several invertebrate sources (1, 8, 15, 26, 48, 55, 64) .
The GATA-1 protein was originally identified as an erythroid DNA-binding factor that interacts with promoters and enhancers of many erythroid cell-specific genes (12, 34, 62) . The isolation of cDNA clones encoding GATA-1 (10, 60) established the primary structure of the GATA factor DNAbinding domain and allowed the isolation of other family members by cross-hybridization to this conserved sequence. The GATA-1 gene is expressed in erythroid cells and in several related myeloid lineages (30, 31, 35, 56, 72) ; a distinct promoter is used to transcribe GATA-1 in testis tissue (20) . Targeted disruption of the GATA-1 gene demonstrated the requirement of this factor for the maturation of terminally differentiating erythroblasts (46, 54) . Numerous erythroid and myeloid cell target genes of GATA-1 action have been identified by mutation of cis elements required for proper cell or developmental regulation (6, 18, 25, 29, 38, 47, 50, 53, 61, 70, 73) . These binding sites are present in promoters, enhancers, or the locus control region responsible for developmental regulation of the globin locus (49, 57) .
The important role of GATA-1 in regulating hematopoietic gene expression is well established, and the GATA-1-DNA interaction has been analyzed extensively. Mutational analysis of the conserved GATA factor zinc finger repeat region has shown that N-terminal finger I is dispensable for DNA binding (33, 66) . The C-terminal finger, together with a cluster of associated basic residues, is necessary and sufficient for sequence-specific recognition and high-affinity binding to the WGATAR cis element (41) . This result facilitated the determination of the solution structure of a finger II peptide bound to a cognate DNA-binding site (40) . Finger I has been shown to contribute to DNA binding by regulating site discrimination and affinity (33, 63, 66) .
By comparison, relatively little is understood regarding how the protein functions as a transcriptional activator. Although GATA-1 must interact with other proteins in the erythroid nucleus, and presumably with some component(s) of the transcription complex, there is no direct evidence of protein targets of GATA-1 in vivo. By deletion analysis, we and others have demonstrated that sequences both N terminal (Act I) and C terminal (Act III) contribute to activation function (33, 66) . We have also found previously that finger I sequences (Act II) can contribute to activity indirectly, by regulating precise binding. However, these loss-of-function experiments do not provide evidence of activating sequences that can function outside the context of the GATA DNA-binding domain. Evidence of independent activating sequences within mouse GATA-1 has been found (33) . Comparative data regarding the chicken protein would be informative, as the two protein sequences are not conserved outside of the DNA-binding domain.
We used the one-hybrid approach to analyze functions of chicken GATA-1 (cGATA-1) distinct from interaction with the WGATAR cis element. After defining precisely the minimal DNA-binding domain, we replaced it with a heterologous DNA-binding domain that confers novel specificity on the protein. We found that sequences outside of the DNA-binding domain are sufficient to provide efficient nuclear localization and high levels of transcriptional activation. Most interestingly, we found evidence of GATA-1 homotypic protein-protein interactions in vivo. We showed that GATA-1 molecules form higher-order structures in solution. This allows GATA-1 to activate gene expression by tethering to a bound transcription factor and may have implications regarding the action of GATA-1 from distant locus control region or enhancer elements.
MATERIALS AND METHODS
Construction of mutations and chimeric cDNA clones. Point mutations of cGATA-1 basic regions were generated from single-stranded phagemid cDNA by using a kit (Amersham) and mismatched oligonucleotides as previously described (66) . For each primer reaction, random clones were picked and sequenced to determine the amino acid changes indicated in Fig. 1 .
The LexA-Swap construct was generated by replacing the cGATA-1 finger II DNA-binding domain with the LexA (amino acids [aa] 1 to 87) DNA-binding domain. cGATA-1 expression plasmid pHY41.2 was digested with SacII (followed by mung bean nuclease treatment) and BssHII (followed by a Klenow fill-in reaction) to delete finger II. pHY41.2 is identical to pHY15.1 (66) containing the wild-type cGATA-1 cDNA, except that an EcoRI-to-PstI portion of the 5Ј untranslated region was deleted to facilitate subcloning. The LexA DNAbinding domain which replaced the SacII-BssHII fragment was isolated from the glucocorticoid receptor (GR)-Swap expression construct (pLx⌬Z [16] ) by digestion with XhoI (followed by mung bean nuclease treatment) and BamHI (followed by a Klenow fill-in reaction). When expressed, the resulting fusion protein FIG. 1. BR2 and BR3 are critical for DNA binding by cGATA-1. (A) Site-directed mutations were introduced into the cGATA-1 cDNA as shown, and the mutated proteins were expressed in transient QT6 cotransfection assays. The activity shown is relative to that of the wild-type (WT) protein and refers to levels of CAT activity from the cotransfected ␣-globin reporter. The data shown are from a single experiment but did not change significantly upon repetition. Basal promoter activity was around 5%. The Western blot demonstrates that all proteins accumulated similarly; lane numbers refer to the mutations. The leftmost lane contained the molecular size standards as indicated on the left (in kilodaltons). As controls, we used extract from primary chicken embryo erythroid cells (RBC), transfected cells expressing wild-type cGATA-1 (WT), and cells transfected with an expression vector containing the wild-type cDNA in the reverse (antisense [AS]) orientation. (B) A gel mobility-shift assay with nuclear extracts from transfected cells demonstrated that the dysfunction of BR2 and BR3 mutations is due to lack of DNA-binding activity. The arrow indicates the GATA-1-DNA complex; P refers to the position of the unbound oligomer ␣-globin probe. Lanes are as in panel A. (C) The BR mutations affect DNA binding by increasing the off rate. The BR2 mutated protein is 169-52, which retains some residual binding activity. The amount of complex remaining, relative to the complex present at the time of competitor addition, is shown as a function of time. Assays were performed and analyzed as described in reference 66. The half-life of each complex is given in Table 1. contains an insertion of glycine-serine at the N terminus of the LexA DNAbinding domain; the proline at position 87 is restored.
To generate hybrids containing individual Act regions, LexA expression vector pHY36.3 was created. The pHY29.1 vector was digested with SalI (followed by a Klenow fill-in reaction) and SacI. A fragment encoding the LexA (aa 1 to 87) DNA-binding domain was isolated from pLx⌬Z by XhoI (followed by a Klenow fill-in reaction) and SacI digestion and was ligated into the vector to create pHY36.3. For each hybrid construct, the cGATA-1 Act derivative was generated by PCR with primers that incorporated HindIII sites at both ends. Ligation of products into the HindIII site of pHY36.3 generated Act derivatives in coding frame with the LexA DNA-binding domain (including an insertion of serineleucine at the fusion site). For superactivation assays, a KpnI-HindIII fragment containing the full-length cGATA-2 cDNA (65) or a BamHI-HindIII fragment containing the full-length cGATA-5 cDNA (27) was ligated into the appropriate sites of the pHY29.1 expression vector. Inserts for each of the GATA-1, Swap, and Act expression constructs were sequenced to verify the coding potential. The LexA-dependent reporters and the LexA-VP16 and LexA-GR expression plasmids used have already been described (16, 32, 36) .
DNA transfection. Avian QT6 fibroblasts were cultured and transfected as previously described (66) . In a standard assay, 5 ϫ 10 5 cells (seeded 18 to 24 h previously) were transfected with 2 g of a Rous sarcoma virus long terminal repeat expression plasmid (containing wild-type cGATA-1 or a derivative), 3 g of a chloramphenicol acetyltransferase (CAT) reporter plasmid under the control of a GATA-dependent ␣-globin promoter, 0.5 g of a pCH110 ␤-galactosidase expression vector as an internal control, and 30 g of lipofectamine (Bethesda Research Laboratories). In the case of chimeric proteins, the reporters display distinct basal levels and were adjusted accordingly; total DNA, the internal control, and the lipofectamine reagent were constant. For LexA derivatives, transfections included 2 g of the LexA expression vector and 0.2 g of XCCO (a LexA-dependent reporter consisting of multiple operator-binding sites fused to the cytomegalovirus promoter at position Ϫ33) or the OCCO control reporter (containing the Ϫ33 cytomegalovirus promoter without operator sites). After 40 h, cells were harvested and a total cell extract was prepared (66) . Lysates containing equal amounts of ␤-galactosidase activity were used in CAT assays, and the results were quantified with an AMBIS Radioanalytic Imaging System. DNA-binding assays. Nuclear extracts were prepared, essentially as previously described (66) , from 6 ϫ 10 7 transfected QT6 cells. Harvested cells were resuspended in 400 l of ice-cold buffer A, incubated on ice for 10 min, and lysed by vortexing for 10 s. Nuclei were pelleted in a microcentrifuge for 10 s at full speed and extracted in 100 l of buffer C for 20 min on ice. The resulting lysate was dialyzed against 50 volumes of buffer D for 5 h at 4ЊC, cleared of cellular debris by centrifugation for 15 min, and stored as a nuclear extract at Ϫ80ЊC.
Gel mobility shift assays and determination of off rates were performed as previously described (66) . Prior to electrophoresis, double-stranded oligomer probes were incubated with nuclear extract for 20 min on ice (GATA-1) or for 30 min at room temperature (LexA derivatives). The sequences of the probes used in this study are as follows, with the relevant binding site underlined and mutations in lowercase (only the top strand is shown): ␣-globin (TE72/73), AGCTTGCGGATAAGATAAGGCCGGAATTCA; -globin (TEPI3), AATT CAGCTCAAGGAGATAAGGGTCCGA; LexA (TE211/212), CCTCGACGT ACTGTATGTACATACAGTAATCCC; LexA half site (TE242/248), CCTCGA CGTACTGTATGTACATACAcTAATCCC; LexA MUT (TE243/249), CCTC GACGTAaTaTATGTACATACAtTAATCCC; LexA ϩ1 (TE244/250), CCTCG ACGTACTGTATGTtACATACAGTAATCCC; LexA ϩ2 (TE245/251), CCTC GACGTACTGTATGTatACATACAGTAATCCC.
DNase I footprinting experiments were performed essentially as previously described (21) . Probes were generated by PCR with primers that flank the promoter region of XCCO, which contains multiple LexA operator-binding sites. Either the 5Ј primer (CTCACTAAAGGGAAC) or the 3Ј primer (CGTCTCCC AGGCGAT) was end labeled with [␥-32 P]ATP by using T4 DNA kinase. One labeled primer and one unlabeled primer were used to amplify the probe from 40 ng of a BspEI-linearized XCCO template in a 40-l PCR (94ЊC, 1 min; 55ЊC, 1 min; 72ЊC, 1 min; 30 cycles). The amplified product was purified after electrophoresis through a 5% polyacrylamide gel. For each reaction, 3 ng of the labeled probe was incubated for 30 min at room temperature with 30 l of total extract in a 50-l volume prior to DNase I digestion. Nuclear extract was from untransfected cells or cells transfected with plasmids expressing LexA-Swap or basic region 2 (BR2) (total protein was always the same; only the ratio of LexA-Swap to BR2 was altered). The concentration of DNase I was determined empirically in preliminary experiments. Following digestion, products were extracted twice with phenol-chloroform, precipitated with ethanol, and analyzed by electrophoresis through a 6% polyacrylamide denaturing gel.
Immunohistochemistry. Nuclear extracts were electrophoresed through sodium dodecyl sulfate (SDS)-12.5% polyacrylamide gels, transferred to polyvinylidene difluoride membranes (Bio-Rad), and analyzed by Western blotting (immunoblotting) by standard procedures (19) . Primary polyclonal antiserum was specific for cGATA-1 (1:1,000 dilution). After secondary incubation with alkaline phosphatase-conjugated goat anti-rabbit immunoglobulin G, detection was visualized with a 5-bromo-4-chloro-3-indolylphosphate (BCIP)-nitroblue tetrazolium substrate.
For immunofluorescence studies, 10 5 QT6 cells were seeded on sterile Corning 22-mm-square coverslips in a 35-mm-diameter petri dish 1 day prior to transfection. Cells were transfected with cGATA-1 or derivative expression vectors as described above. After 48 h, coverslips were washed three times with ice-cold phosphate-buffered saline (PBS) and fixed for 5 min at room temperature in 1 ml of methanol (Ϫ20ЊC). Cells on coverslips were then washed three times with PBS and incubated with rabbit anti-cGATA-1, anti-LexA, or control (preimmune) serum for 1 h at 37ЊC. Cells were washed with PBS and then incubated secondarily with fluorescein isothiocyanate-labeled goat anti-rabbit immunoglobulin (Sigma). The cells were simultaneously incubated with 4Ј,6-diamidino-2-phenylindole (DAPI) to permit visualization of nuclei. Staining was visualized and photographed with a fluorescence microscope (Nikon).
For immunoprecipitation studies, the labeled cGATA-1 protein was generated in vitro as described previously, except that a TNT kit (Promega) was used (10) . This labeled protein has been shown previously to generate functional GATA-1 DNA-binding activity (10) . Following translation, 100 l of the reticulocyte lysate was mixed with 300 l of RIPA buffer (10 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, various protease inhibitors) and 100 l of QT6 nuclear extract. The nuclear extract was derived either from untransfected cells or from cells transfected with the LexA-Swap expression vector. After addition of 1 l of rabbit anti-LexA antibody, the mixture was incubated at 4ЊC for 2 h. Protein A-Sepharose beads (150 l of a 50-mg/ml stock; Pharmacia) were added, and the incubation was continued for 2 h. Immune complexes were pelleted, and the beads were washed six times with RIPA buffer (1% Nonidet P-40). Protein pellets were resuspended in SDS sample buffer and boiled prior to electrophoresis through SDS-12.5% polyacrylamide gels. Labeled protein was detected by fluorography (National Diagnostics).
RESULTS
Determination of the minimal DNA-binding domain: function of basic regions within the conserved finger regions. In previous work (66), we defined by deletion analysis regions of the cGATA-1 protein that contribute to DNA binding and transcriptional activation. In our standard assay (11), cGATA-1 derivatives are expressed from a Rous sarcoma virus long terminal repeat-regulated plasmid in avian QT6 cells, which lack the erythroid factor. The abundance and stability of the expressed protein are analyzed by Western blotting of transfected cell extracts. DNA-binding activity is measured by a gel mobility shift assay by using cell extracts and an oligomer probe containing a well-characterized GATA-1-binding site. The ability of cGATA-1 or derivative proteins to activate transcription is tested by cotransfecting a target reporter gene consisting of an ␣-globin promoter fused to the CAT gene; this promoter is entirely dependent on GATA-1 for activity. Thus, measurement of accumulated CAT activity provides a relative indication of the ability of expressed proteins to activate transcription. We are also able to analyze the ability of expressed proteins to localize properly to the nucleus by using immunofluorescence techniques.
Previous studies of sequences that contribute to GATA-1 binding have largely been carried out by deletion analysis, which may grossly disrupt protein structure. We and others (33, 66) have demonstrated by point mutations the importance of finger II cysteines, but these mutations are also likely to radically alter structure and may have indirect effects on activation domains. We sought to analyze the relative contribution of finger region sequences to DNA binding by introducing mutations outside of the cysteine-rich region to better define the specific borders of the DNA-binding domain. Part of our goal for the experiments described below was to identify mutations that abolish DNA binding in the context of the entire protein without disrupting the structure of activation domains.
Within the cGATA-1 protein, we targeted four stretches of basic amino acids (BRs) for site-directed mutagenesis (Fig.  1A) . BR1 is located at the C terminus of finger I (just N terminal to the beginning of finger II), while BR2, BR3, and BR4 are located at the C terminus of finger II. Our previous deletion analysis (66) and results obtained with short peptides (41) indicated that some elements of BR2 to BR4 are required for sequence-specific DNA binding. BR1 and BR2 are located at analogous positions in fingers I and II, respectively. Muta- tions were introduced to change two amino acids of each individual BR, and the mutated proteins were expressed in cotransfection assays. The effect of altering BR amino acids is shown in Fig. 1A . Each mutated protein is stable and accumulates in transfected cells similarly to the wild-type protein. The BR1 and BR4 mutations have no effect on the ability of the protein to activate transcription. However, mutation of BR2 or BR3 severely diminishes activity. In BR2, the most severe mutations involve alteration of a lysine to a glutamic acid. Gel mobility shift assays with extracts from transfected cells confirmed that the mutations affect activity at the level of DNA binding (Fig. 1B) . The ability of BR2 mutant protein 169-52 to retain some binding activity is reflected in the low but significant level of activation of the reporter.
It was somewhat surprising that BR1 mutations had no effect on activity, as previous deletions or cysteine mutations of finger I showed at least a twofold drop in transactivation, related to an increased off rate of the protein on DNA. To further characterize the effects of BR1 and BR2 mutations (located at the analogous position in each finger) on DNA binding, we performed off-rate measurements with extracts containing these proteins and compared the results to the off rate of the wildtype protein (Fig. 1C) . Consistent with our previous deletion data, we found that the BR1-mutated protein showed a twofold increase in the off rate relative to the wild-type protein, with either a high-affinity ␣-globin promoter probe or a loweraffinity -globin promoter oligomer (Table 1 ). Failure to detect a defect in transcriptional activation is likely due to saturating amounts of the expressed protein. Likewise, the 169-52 finger II BR2 mutation, which demonstrates residual binding activity, showed a very large increase in the off rate (a 30-fold increase relative to the wild-type protein). We concluded that the primary function of both BR1 and BR2 involves regulation of DNA affinity; in both cases, the associated basic residues are essential, in addition to the cysteine-rich regions, for the function of the finger. The finger II DNA-binding domain requires both BR2 and BR3 for sequence-specific DNA interaction. Certain mutations of either BR2 or BR3 are sufficient to inactivate the DNA-binding function, even in the context of the entire protein. These mutations are unlikely to alter the structure of any putative activation domains, as these amino acids are thought to lie in an unstructured C-terminal tail of the DNA-binding domain (40) .
Function of activation sequences in the context of a heterologous DNA-binding domain. By loss-of-function deletion analysis, we have identified regions (Act I, Act II, and Act III) which contribute to transcriptional activation. Act II was mapped within finger I, and the evidence indicated that Act II contributes primarily by regulating precise alignment of the protein on DNA (66) . In all of these previous experiments, the putative activation domains were analyzed in the context of the native GATA-1 DNA-binding domain (finger II). We sought to determine (i) whether activating sequences distinct from GATA-1 DNA-binding sequences could be detected and (ii) whether such activation domains could be localized and analyzed (by gain of function) in the context of a heterologous DNA-binding domain. For this purpose, we replaced the defined GATA-1 DNA-binding domain with the minimal DNAbinding domain derived from bacterial repressor protein LexA (aa 1 to 87; creating the LexA-Swap protein). A plasmid expressing the LexA-Swap protein was cotransfected into QT6 cells with a reporter CAT gene regulated by a promoter containing LexA DNA-binding sites.
The LexA-Swap protein activated the reporter containing LexA operator sites nearly 30-fold, which is comparable to (threefold lower than) the activity of a LexA-VP16 hybrid ( Fig.  2A) . Note that, as expected, the GATA-1 BR2 mutant 169-42 protein was unable to activate the LexA reporter. On the basis of our previous deletion data (Fig. 2B) , and taking into account known exon-intron boundaries, sequences identified as Act I (aa 1 to 106), Act II (aa 107 to 158), and Act III (aa 227 to 304) were fused as independent units to the LexA DNA-binding domain and expressed in QT6 cells. None of these fusion proteins was able to activate the LexA reporter, although each was shown (by using an anti-LexA antibody) to be expressed at a level comparable to that of LexA-Swap (data not shown).
There are several explanations for the failure of individual Act domains to function when fused to LexA 1-87. This LexA segment does not contain nuclear localization signals or the DNA dimerization region thought to be required for stable interaction with the LexA operator (22, 51) . By comparison, we were able to identify and define independent activation sequences when Act domains were fused instead to the DNAbinding domain of yeast activator GAL4, which provides localization and dimerization functions (unpublished data). The Individual putative activation sequences were tested independently, but the LexA fusion proteins containing them were unable to bind to DNA. Act regions I to III were defined by deletion studies; the illustration is taken from reference 66. a Half-lives of complex as determined by off-rate analysis with a large excess of cold competitor were determined for the wild-type (WT), BR1 (mutation 168-44), and BR2 (mutation 169-52) proteins. Times were calculated from the data shown in Fig. 1C as previously described (66 fact that the LexA-Swap protein is also able to activate transcription of the target reporter indicates that functional elements providing nuclear localization and protein dimer stabilization at the palindromic operator site must reside within the GATA-1 protein itself but distinct from the finger II DNAbinding domain. The ability of GATA-1 sequences to facilitate binding at a dimer site is interesting, as all previous data have indicated that GATA-1 binds to its cognate site as a monomer. Therefore, the abilities of LexA-Swap to localize to the nucleus and bind at a dimer site were tested directly. Localization and homotypic interaction functions of GATA-1 lie outside the DNA-binding domain. QT6 cells were transfected with plasmids expressing wild-type cGATA-1, the LexASwap protein, or LexA-Act derivatives. Cells were fixed and analyzed by immunohistochemistry by using cGATA-1 or LexA antibodies and secondary antibodies conjugated to fluorescein isothiocyanate. Cells were also stained with DAPI to determine the positions of nuclei. The results (Fig. 3) show that both the wild-type and Swap proteins localize to the nucleus and support the notion that one or more nuclear localization signals reside in GATA-1 at locations distinct from the DNA-binding domain. LexA sequences fused to either Act I or Act III remain predominantly cytoplasmic. Only the Act II fusion protein can localize to the nuclear compartment. For both the Swap and Act II fusions, the nuclear staining appears punctate and perinuclear compared with the wild-type protein and may therefore not be entirely normal. However, Act II (finger I) appears to contain sequences sufficient for nuclear localization.
The interaction of the LexA-Swap protein with operator sequences was investigated in vitro by using a gel mobility shift assay. The primary complex formed with the normal palindromic operator site appears to involve the binding of two swap protein molecules to the operator sequence (Fig. 4) . The putative dimer complex forms in a concentration-dependent manner, which is consistent with cooperative binding (Fig. 4A  and D) . The Swap protein has approximately the same molecular size as wild-type GATA-1. However, the migration of the Swap-operator complex was much less than that of a GATA-1-DNA complex (similar to the migration of two molecules of GATA-1 bound independently to an oligomer probe; data not shown, but see Fig. 4C ). Competition experiments demonstrated that the complex is specific for the operator sequence (Fig. 4B) . Moreover, the dimer complex was unable to form on an oligomer probe that contains only one operator half site or in which the spacing between half sites has been altered (Fig.  4C) . In this case, only a small amount of a monomer complex (comigrating with the wild-type GATA-1 complex) was detected. We concluded that sequences that stabilize a SwapSwap interaction on the LexA operator are present within the cGATA-1 protein. Although these may not represent a true dimerization domain, they are sufficient to permit GATA-1 self-association to stabilize bound protein and activate transcription.
We attempted to use the LexA system to localize GATA-1 sequences that are independently capable of contributing to homotypic interaction or transcriptional activation. In some cases, sequences that encode the simian virus 40 T-antigen nuclear localization signals were inserted in frame with the LexA fusion proteins to ensure efficient localization to the nucleus. However, none of the nucleus-localized LexA-Act constructs was capable of activating the reporter plasmid, although each was expressed stably (data not shown). Gel mobility shift experiments demonstrated the inability of these proteins to bind to the operator site. Only the Swap protein was capable of interacting stably with the operator. We concluded that no single Act region can provide the homotypic interactions detected with the intact Swap protein. We note that some very weak binding to the operator has been detected by using the Act III fusion protein, but this is inconsistent and apparently too unstable to facilitate transcriptional activation. Therefore, sequences both N and C terminal of the DNAbinding domain are required on a GATA-1 molecule to mediate stable binding to the operator site. Homotypic interactions can facilitate transcriptional activation. The ability of the LexA-Swap protein to function as an activator from a dimer-binding site indicated that GATA-1 sequences may facilitate stable binding through homotypic protein interactions. If this is the case, we predicted that such interactions might still occur in non-DNA-binding forms of GATA-1. We reasoned that by providing a bound target for GATA-1, homotypic interactions might be revealed by bringing the nonbinding form to the promoter via the bound form, leading to higher levels of transcription (superactivation). In these experiments, the target (binding) form was provided at subsaturating levels as an activator and the non-DNA-binding form was coexpressed as a superactivator. We have expressed LexA-Swap as an activator and asked whether BR2 GATA-1 mutant 169-42 (which is unable to bind to DNA but might still maintain the activation domain structure) is able to function as a superactivator (Fig. 5A) .
The results of such an experiment are shown in Fig. 5B . Coexpression of the BR2 mutant protein led to superactivation of the LexA-Swap protein. When the LexA-Swap protein was expressed alone at minimal levels (by transfection of only 50 ng of the expression plasmid), the level of reporter activation was small (severalfold). Coexpression of increasing amounts of the non-DNA-binding BR2 mutant expression plasmid led to increasing levels of reporter activity. Strikingly, in the presence of the bound activator, the superactivator appeared to be as potent as the activator itself. Addition of a twofold excess of the superactivator expression plasmid resulted in a 2.5-fold increase in CAT activity. Transfections including a 10-fold excess of the BR2 expression construct led to a ninefold increase in transactivation. At increased superactivator excesses, the effect appeared to saturate, resulting ultimately in the approximately 30-fold activation potential seen when excess LexA-Swap protein alone was used. Transfection of the maximal amount of the BR2-expressing plasmid in the absence of the LexA swap construct resulted in no activity (last lane). Therefore, all of the activity of the superactivator is dependent on the bound activator protein.
The mechanism of superactivation is not at the level of DNA binding but involves protein-protein interaction. There are at least two alternative interpretations that could explain the ability of GATA-1 to superactivate, besides homotypic interactions that facilitate tethering of the superactivator to promoter DNA. For example, the superactivator may function indirectly by stabilizing the binding of the activator protein. Alternatively, the expressed superactivator might not interact with GATA-1 but might instead titrate out a repressor that normally inhibits the bound activator.
To test the first possibility, that the superactivator stabilizes the binding of the activator protein, we used DNA-binding assays. Gel mobility shift assays were performed by using the LexA palindromic binding site and mixtures of extracts from transfected cells expressing either the LexA-Swap protein or the superactivator BR2 protein. These extracts were shown by Western blotting, with a polyclonal anti-cGATA-1 antibody, to contain comparable amounts of the respective proteins (data not shown). As expected, the LexA-Swap protein formed a complex with DNA while the BR2 protein was unable to bind to DNA (Fig. 6A) . The presence in the binding reaction of increasing amounts of the BR2 protein had no effect on binding by the LexA-Swap protein. Nevertheless, this ratio of BR2 to LexA-Swap led to significant superactivation in vivo.
As a second independent approach to the determination of whether the superactivator functions at the level of DNA binding, we performed DNase I footprinting experiments. Nuclear extracts from cells transfected with the LexA-Swap protein contained binding activity that protected the operator sequences from nuclease digestion (Fig. 6B ). Under these conditions, operator sequences were occupied when 10 l, but not when 5 l, of nuclear extract was used. Addition of increasing 
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on February 21, 2013 by PENN STATE UNIV http://mcb.asm.org/ amounts of the BR2 protein (in the presence of 5 l of LexASwap) had no effect on binding and did not lead to operator occupancy. Therefore, we concluded that the BR2 protein activates transcription not by promoting stabilization of the bound Swap protein or increasing the affinity of the Swap protein for DNA but rather via tethering to the promoter region by protein-protein interactions. We next considered the second possibility, that the expressed superactivator does not interact with GATA-1 but instead titrates out a repressor. We expected that if this were the case, the superactivator would not form a complex in solution with GATA-1. Therefore, we designed an experiment to test directly for the formation of a complex containing the LexA-Swap and GATA-1 proteins in solution. The radiolabeled GATA-1 protein was generated in vitro by using a reticulocyte lysate. This labeled GATA-1 protein was then mixed in vitro with an extract derived from QT6 cells transfected with the LexA-Swap expression plasmid. We used an anti-LexA antibody to immunoprecipitate the LexA-Swap protein.
The precipitate was then analyzed by SDS-polyacrylamide gel electrophoresis followed by fluorography. We expected that if the labeled GATA-1 protein forms a complex in solution with the LexA-Swap protein, it should be present in the immunoprecipitate. Indeed, the labeled protein was present in the pellet precipitated by an anti-LexA antibody (Fig. 7) . As a control, a lysate from QT6 cells that did not express LexA-Swap was used. In this case, no GATA-1 protein was precipitated. Also, no labeled GATA-1 protein was precipitated when irrelevant antibodies were used in place of anti-LexA as the primary antiserum (data not shown). Therefore, the ability of LexA antibodies to precipitate GATA-1 is completely dependent on the presence of LexA-Swap. We concluded that homotypic interactions do occur and that GATA-1-GATA-1 complexes form in solution. We have no way of knowing whether this interaction is direct or requires an auxiliary protein(s).
Superactivation from distinct bound activator proteins. We used the superactivation assay to determine whether the cGATA-1 BR2 protein can activate transcription by targeting to other promoter-bound proteins. In our first approach, two distinct proteins were tested for the ability to be targeted. In each case, a suboptimal amount of activator was expressed to provide a low level of reporter CAT activity; increasing amounts of a BR2 expression plasmid were then cotransfected to test for superactivation (Fig. 8A) . We found that the LexA-VP16 fusion protein could not be superactivated. This result indicates that the interaction of the BR2 protein with the LexA-Swap protein is not directed by the LexA portion of the Swap protein. More similar to the LexA-Swap results, a LexA-GR (GR-Swap) protein was capable of being superactivated over 10-fold. These results indicate that some bound activators (for example, derived from GATA-1 or GR) are capable of providing a target for superactivation, while others (for example, VP16) are not.
Finally, we analyzed the ability of distinct GATA factors to interact with GATA-1. This question is pertinent because different GATA factors are coexpressed in distinct subsets of progenitors and differentiated cell types. For example, the GATA-1, GATA-2, and GATA-3 genes are each expressed in hematopoietic cells (43) , while the GATA-4, GATA-5, and GATA-6 genes have all been implicated in the regulation of cardiovascular and gut development (27) . As representative of each class, we tested the ability of GATA-2 or GATA-5 to superactivate the bound LexA-Swap protein. Expression of either protein alone in a cotransfection assay did not activate the LexA reporter. We know that functional proteins were expressed, because each could transactivate the target ␣-globin promoter (33-fold for GATA-2 and 12-fold for GATA-5; data not shown). Interestingly, hematopoietic factor GATA-2 was able to superactivate the LexA-Swap protein in a manner similar to that of GATA-1, while cardiac-gut factor GATA-5 was unable to do so (Fig. 8B) . 
DISCUSSION
We replaced the cGATA-1 DNA-binding domain with that of a heterologous protein to demonstrate that transcriptional activating sequences which can function independently are present in cGATA-1. Our results obtained with the LexA DNA-binding domain are informative, as LexA 1-87 does not provide nuclear localization or protein dimerization sequences. We found that sequences outside of the normal cGATA-1 DNA-binding domain can provide these functions in addition to activating transcription. This is the first time activating sequences have been demonstrated for cGATA-1 by a gain-of-function assay and the first time any evidence has been found that GATA factors can self-associate in a manner that productively influences gene expression.
Because sequences both N terminal and C terminal are required for mediation of stable binding to the LexA operator, this system has not been useful for mapping of independent activation sequences. Instead, we recently used a GAL4 DNAbinding domain to map very potent activating sequences within Act I (unpublished data). However, the LexA-Swap protein is localized to the nucleus, demonstrating that sequences influencing this process are present outside of the DNA-binding domain. In the case of the Swap protein, localization appears to be leaky; finger II or associated BRs might therefore contribute to the process. The Act II fusion protein also accumulates in the nucleus, which indicates that finger I may contain a nuclear localization signal. This is consistent with the findings of Yang et al. (67) regarding human GATA-3. They found that proteins with finger I deleted failed to localize properly to the nucleus. Nuclear localizing sequences have been shown to be associated with distinct types of zinc fingers (37 and references therein). The pattern of immunofluorescence for the LexA-Act II protein appears to be somewhat aberrant (punctate and perinuclear) relative to that of the wild-type protein, indicating that additional sequences (presumably associated with finger II) may contribute to fully regulated localization. We analyzed the effects of mutations in individual BRs of finger I (BR1) and finger II (BR2 to BR4) and in specific finger region cysteines. We found no defect in localization for any of these individual mutations (data not shown). Although finger I is likely to be involved, the GATA-1 nuclear localization signal may be complex and partitioned into multiple distinct and dispersed sequences, as is the case for several other well-characterized factors (68) .
The minimal LexA DNA-binding domain requires cooperative interaction on the DNA to stabilize the complex (4, 52, 59) . Other proteins that have been shown to function as LexA (1-87) fusions are thought to employ natural dimerizationinteraction domains to provide this cooperativity (28, 39) . GATA-1 binds to its cognate site as a monomer, and there is no evidence that it is capable of forming a dimer (10, 40) . Thus, it is a striking finding that the LexA-Swap protein can function as a potent transcriptional activator. This is strong evidence that GATA-1 can make functional homotypic interactions that are able to stabilize binding to a palindromic cis element. The protein binds with apparent cooperativity (showing concentration dependence) to this site and cannot interact stably with a half site. We suggest that sequences outside of the GATA-1 DNA-binding domain can function for GATA-1 self-interaction and thereby stabilize the activator at the palindromic operator. It is possible that this interaction is relatively weak or transient (24) , as we did not detect it in the DNA-binding assays (e.g., as a supershift). However, we did show by coimmunoprecipitation experiments that homotypic interactions can result in complex formation in solution. The transcription assay is extremely sensitive to this homotypic stabilization, and so we detected it readily in the cotransfection assay. It has been noted previously that heterologous peptides might stabilize LexA binding through a protein-protein interaction that is independent of true dimerization sequences (17) .
We attempted to map the region of cGATA-1 necessary for this self-interaction. We detected very weak binding of the LexA-Act III fusion protein to the operator site. This may indicate that part of the function of Act III is to promote higher-order GATA complexes. However, stability was far less than that seen with the Swap protein and is clearly not sufficient for full activity. Other combinations of individual Act domains did not stabilize binding. This is consistent with the lack of a true dimerization domain and the presence of an interaction surface that may function well only in the context of the full protein (but does not require finger II).
The ability of a DNA-binding-deficient GATA-1 protein to superactivate the LexA-Swap protein greatly strengthens the notion that GATA-1 can self-associate and do so in a manner that affects gene expression. The result is not related to the LexA DNA-binding domain, because the superactivator BR2 protein is not a fusion protein and BR2 is unable to activate LexA-VP16. It is likely that the structure of BR2 is very similar to that of wild-type GATA-1, as only two amino acids in the unstructured portion of the DNA-binding domain are altered. While this protein is unable to activate gene expression by itself because of the nonfunctional DNA-binding domain, it is a strong activator when coexpressed with a minimal amount of Swap protein, which binds to the operator and acts as a target to tether the BR2 protein at the promoter. Similar results were obtained by using zinc finger mutations of Sp1, which can superactivate a target promoter by interacting with bound Sp1 (44) . The formation of higher-order Sp1 complexes has been Fig. 5B. ( A) The BR2 protein is able to superactivate a LexA-GR hybrid (top) but not a LexA-VP16 hybrid (bottom). For the latter experiment, less LexA-VP16 was used because of its higher activity. However, similar results were obtained (no superactivation) when larger amounts of LexA-VP16 were used (data not shown). (B) Overexpressed cGATA-2 (top), but not overexpressed cGATA-5 (bottom), is able to superactivate the LexA-Swap protein. (45) , although GATA-1-binding proteins were not identified. In theory, we can use this system to identify other factors with which cGATA-1 can interact productively. We need simply to analyze the ability of the BR2 protein to target and thereby superactivate a bound activator. In our first tests of this system, we found that cGATA-1 does not superactivate the LexA-VP16 activator but is able to superactivate a LexA-GR activator. This might indicate that GATA-1 is unable to interact with VP16 but can interact with GR. Previously, some evidence has been presented that GATA-1 and GR can interact in vitro (5) . Again, this may be a relatively transient interaction which could be detected readily in vivo because our transcription assay is extremely sensitive.
Our data indicate that the ability of LexA-Swap to bind stably to a palindromic operator site and that of BR2 to superactivate bound LexA-Swap involve protein-protein interactions among GATA-1 derivatives. This interaction does not function at the level of DNA binding, as our gel shift and footprint assays demonstrated that excess superactivator does not increase the efficiency of binding site occupancy. Furthermore, we demonstrated by coimmunoprecipitation assays that GATA-1 derivatives form complexes in solution in the absence of DNA binding. The superactivation assay demonstrated that productive interactions can occur between GATA-1 and GATA-2 but not between GATA-1 and GATA-5. This result makes it seem unlikely that the conserved GATA DNA-binding domain plays a role in mediating protein-protein interaction (also consistent with the ability of the LexA-Swap protein to interact with GATA-1). Furthermore, the ability of GATA-1 to interact functionally with some, but not all, activators demonstrates that the superactivator does not interfere with any general repressor and might indicate that auxiliary cellular proteins function to mediate specific interactions between GATA-1 and various classes of activators.
Regardless of the mechanistic details of superactivation, the fact that it works has potentially important implications regarding the function of GATA-1. Numerous erythroid cis elements have been shown to consist of multiple complex WGA-TAR binding sites (12, 34, 53, 61) . Binding sites for GATA-1 are located in promoters, enhancers, and distant locus control region sequences which must somehow communicate with each other for regulated gene expression. Models that support directed interaction of distant regulatory elements in the regulation of erythroid gene expression have been tested (7, 9, 13) . For example, binding sites for GATA-1 in the 3Ј chicken ␤-globin enhancer and a specialized GATA box in the promoter are thought to function in the regulation of globin expression by a looping mechanism (3, 14) . The ability of GATA-1 to selfassociate may not be important for transactivation from certain local promoter elements. Instead, GATA-1 homotypic interactions might facilitate the looping required for distal elements to interact functionally.
